Published in Int J Womens Health on October 27, 2010
Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci (2011) 0.91
Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors. BMC Pharmacol (2012) 0.83
Lubiprostone induced ischemic colitis. World J Gastroenterol (2013) 0.78
Lubiprostone for the treatment of adult women with irritable bowel syndrome with constipation. Clin Med Insights Gastroenterol (2012) 0.76
Gender-related differential effect of tachykinin NK2 receptor-mediated visceral hyperalgesia in guinea pig colon. Br J Pharmacol (2016) 0.75
Functional bowel disorders. Gastroenterology (2006) 20.72
U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci (1993) 7.98
Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol (2006) 3.30
Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology (1990) 2.75
Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology (1997) 2.71
Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology (2002) 2.52
Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci (2002) 2.46
SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol (2004) 2.33
Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology (2003) 2.32
Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther (2007) 2.09
Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther (2007) 2.08
International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol (2009) 2.06
Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther (2008) 2.06
Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther (2001) 2.04
Gender differences in irritable bowel syndrome. Gastroenterology (2002) 1.98
Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology (2006) 1.97
Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology (1997) 1.94
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2006) 1.94
Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther (2004) 1.92
The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med (1992) 1.85
Expression of the chloride channel ClC-2 in the murine small intestine epithelium. Am J Physiol Cell Physiol (2000) 1.75
Efficacy of linaclotide for patients with chronic constipation. Gastroenterology (2010) 1.71
Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther (2004) 1.70
Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther (2002) 1.67
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther (1999) 1.66
Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology (2009) 1.59
Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol (2007) 1.57
Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol (2008) 1.54
Epidemiology of irritable bowel syndrome in the United States. Gastroenterology (1990) 1.52
Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther (2008) 1.50
Gender-related differences in IBS symptoms. Am J Gastroenterol (2001) 1.47
Distribution of ClC-2 chloride channel in rat and human epithelial tissues. Am J Physiol Cell Physiol (2002) 1.44
Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol Ther (2004) 1.42
The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut (2002) 1.39
Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol (2008) 1.35
A synthetic prostone activates apical chloride channels in A6 epithelial cells. Am J Physiol Gastrointest Liver Physiol (2008) 1.35
Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil (2007) 1.33
Modulation of the hyperpolarization-activated Cl- current in human intestinal T84 epithelial cells by phosphorylation. J Physiol (1996) 1.25
Lubiprostone: a chloride channel activator. J Clin Gastroenterol (2007) 1.24
Gender differences in regional brain response to visceral pressure in IBS patients. Eur J Pain (2000) 1.23
Distinct populations of sensory neurons mediate the peristaltic reflex elicited by muscle stretch and mucosal stimulation. J Neurosci (1994) 1.19
Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci (2009) 1.19
Basolateral ClC-2 chloride channels in surface colon epithelium: regulation by a direct effect of intracellular chloride. Gastroenterology (2004) 1.15
Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice. Am J Physiol Lung Cell Mol Physiol (2008) 1.14
Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. Am J Physiol Regul Integr Comp Physiol (2006) 1.14
Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon. Am J Physiol Gastrointest Liver Physiol (2009) 1.12
A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol (2005) 1.11
Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol (2008) 1.09
Review article: new receptor targets for medical therapy in irritable bowel syndrome. Aliment Pharmacol Ther (2010) 1.06
Effects of lubiprostone on human uterine smooth muscle cells. Prostaglandins Other Lipid Mediat (2008) 1.05
Lubiprostone stimulates duodenal bicarbonate secretion in rats. Dig Dis Sci (2009) 1.03
Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans. Am J Physiol Lung Cell Mol Physiol (2009) 1.02
Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am J Gastroenterol (2009) 0.95
Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother (2009) 0.94
Role of progesterone signaling in the regulation of G-protein levels in female chronic constipation. Gastroenterology (2005) 0.93
PKA and arachidonic acid activation of human recombinant ClC-2 chloride channels. Am J Physiol Cell Physiol (2000) 0.92
Gender differences in irritable bowel syndrome. J Gend Specif Med (2002) 0.90
Emerging drugs for chronic constipation. Expert Opin Emerg Drugs (2009) 0.89
Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther (2006) 0.88
Abdominal symptoms are not related to anorectal function in the irritable bowel syndrome. Scand J Gastroenterol (1999) 0.84
Lubiprostone: RU 0211, SPI 0211. Drugs R D (2005) 0.83
Irritable bowel syndrome medications side effects survey. J Clin Gastroenterol (2004) 0.82
Lubiprostone: viewpoints. Drugs (2006) 0.81
The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation. Gastroenterology (2008) 0.81
Expression and function of CLC and cystic fibrosis transmembrane conductance regulator chloride channels in renal epithelial tubule cells: pathophysiological implications. Chang Gung Med J (2007) 0.79
Lubiprostone (amitiza) for chronic constipation. Med Lett Drugs Ther (2006) 0.76
Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol (2012) 1.60
Impact of fentanyl in lieu of meperidine on endoscopy unit efficiency: a prospective comparative study in patients undergoing EGD. Gastrointest Endosc (2013) 1.42
A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol (2012) 1.21
C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Med (2011) 1.16
Performance of the patency capsule compared with nonenteroclysis radiologic examinations in patients with known or suspected intestinal strictures. Gastrointest Endosc (2011) 0.91
Emerging drugs for chronic constipation. Expert Opin Emerg Drugs (2009) 0.89
Impact of anal incontinence on psychosocial function and health-related quality of life. Dig Dis Sci (2007) 0.84
Personality traits and impaired health-related quality of life in patients with functional gastrointestinal disorders. Clin Gastroenterol Hepatol (2009) 0.81
Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation. Curr Opin Investig Drugs (2007) 0.81
Antidepressants in the treatment of irritable bowel syndrome and visceral pain syndromes. Curr Opin Investig Drugs (2004) 0.80
Esophageal peristaltic defects in adults with functional dysphagia. Dysphagia (2014) 0.77
Self-dilation as a treatment for resistant, benign esophageal strictures. Dig Dis Sci (2013) 0.77
Diagnosis and management of chronic constipation. JAAPA (2006) 0.77
Self dilation as a treatment for resistant benign esophageal strictures: outcome, technique, and quality of life assessment. Dig Dis Sci (2011) 0.76
Constipation: Linaclotide--a stimulating new drug for chronic constipation. Nat Rev Gastroenterol Hepatol (2010) 0.75
Spectrum of Autonomic Nervous System Impairment in Sjögren Syndrome. Neurologist (2017) 0.75